Physician profile
Gian-Carlo Giove
NPI 1700194966
$231,246.89
in general payments reported to CMS, 2019-2025
40 companies · $31K in 2025
The $31K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $15K · 2021: $24K · 2022: $65K · 2023: $35K · 2024: $39K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Food and Beverage: $19K · Travel and Lodging: $17K · Consulting Fee: $7,178 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,176.50 |
| Food and Beverage | $18,916.07 |
| Travel and Lodging | $16,638.42 |
| Consulting Fee | $7,178.00 |
| Education | $118.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $73,967.37 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42,082.24 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $33,225.32 | 2019-2025 | |
| Lilly USA, LLC | $25,787.22 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $17,045.78 | 2019-2025 | Farxiga, Brilinta, Wainua |
| Bridgebio Pharma, INC. | $11,110.00 | 2025 | Attruby |
| Pfizer INC. | $5,027.68 | 2019-2025 | |
| United Therapeutics Corporation | $2,587.66 | 2019-2025 | Tyvaso, Orenitram, Orenitram |
| Cvrx, INC. | $2,442.68 | 2023-2025 | Barostim Neo System |
| Amgen INC. | $2,420.58 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,865.76 | 2019-2025 | |
| Abiomed | $1,725.52 | 2020-2025 | Impella |
| Actelion Pharmaceuticals US, INC. | $1,572.19 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Abbott Laboratories | $1,476.65 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Viewmate |
| E.R. Squibb & Sons, L.L.C. | $1,316.70 | 2019-2025 | Camzyos, Eliquis |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,287.59 | 2019-2025 | Lifevest |
| Medtronic, INC. | $1,268.27 | 2021-2025 | Symplicity G3, Corevalve Evolut R, Onyx Frontier |
| Alnylam Pharmaceuticals INC. | $1,038.94 | 2021-2025 | Onpattro, Amvuttra |
| Novo Nordisk INC | $735.12 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Aop Health US, LLC | $632.86 | 2025 | Rapiblyk |
| Janssen Pharmaceuticals, INC | $453.34 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $337.59 | 2019-2022 | |
| Medtronic Vascular, INC. | $309.16 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $256.46 | 2025 | Assure Wcd |
| Boston Scientific Corporation | $222.01 | 2021-2024 | Watchman Access System |
| Lexicon Pharmaceuticals, INC. | $212.21 | 2023-2024 | Inpefa |
| Scpharmaceuticals INC. | $199.37 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $117.85 | 2019-2024 | Livalo |
| Cmp Pharma, INC. | $92.35 | 2020 | |
| Daiichi Sankyo INC. | $80.42 | 2023-2025 | Injectafer |
| Impulse Dynamics (USA) INC. | $79.83 | 2021-2024 | Optimizer, Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $67.72 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $53.26 | 2024-2025 | Nexletol |
| Sandoz INC. | $40.05 | 2025 | Treprostinil |
| Sanofi-Aventis U.S. LLC | $37.46 | 2019 | |
| Philips North America LLC | $19.26 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Cardiac Dimensions, INC. | $14.83 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $14.22 | 2023 | Arcalyst |
| Liquidia Technologies, INC. | $11.88 | 2025 | Yutrepia |
| Procyrion, INC. | $11.49 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gian-Carlo Giove listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.